Valeant Pharmaceuticals climbed 9% in the wake of its decision to appoint a new chief financial officer. Paul Herendeen took over the job, coming over from animal health specialist Zoetis. The move allows former CFO Rob Rosiello to focus on corporate development as executive vice president in that role, and it also puts Valeant in an even stronger position to put allegations of accounting issues that led to financial restatements behind the company. Valeant still faces plenty of substantive challenges, but just the awareness that having new people in leadership roles could make it easier for the company to move forward with a new strategy shows that the drugmaker is doing its best to recover from its poor performance recently.